Premium
Why do cannabinoids not show consistent effects as analgetic drugs in multiple sclerosis?
Author(s) -
Lienau F. S.,
Füllgraf H.,
Moser A.,
Feuerstein T. J.
Publication year - 2007
Publication title -
european journal of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.881
H-Index - 124
eISSN - 1468-1331
pISSN - 1351-5101
DOI - 10.1111/j.1468-1331.2007.01903.x
Subject(s) - medicine , multiple sclerosis , peripheral , neuroscience , bioinformatics , psychiatry , psychology , biology
The effectiveness of cannabinoids (CB) in the treatment of pain in patients with multiple sclerosis (MS) varies. The pathogenesis of pain in MS is diverse as are the possible effects of CB at different sites of CB receptors in the peripheral and central nervous system, this may explain the variable impact on individual patients. The aim of this review is to summarize pre‐clinical and clinical studies to explain this variability from a neuropharmacological point of view. Future studies are needed to examine specific effects on distinct symptoms in homogenous groups of patients.